Immune checkpoint inhibitor myocarditis

Current Opinion in Cardiology

Volumn 34, Issue 3, 2019, Pages 303-306

  Raikhelkar, Jayant ^a   Uriel, Nir ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

cardio oncology; cardiotoxicity; immune checkpoint inhibitor; myocarditis

Indexed keywords

BIOLOGICAL MARKER; IMMUNE CHECKPOINT INHIBITOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CASE FATALITY RATE; CLINICAL FEATURE; DISEASE SURVEILLANCE; HEART MUSCLE BIOPSY; HEMODYNAMICS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYOCARDITIS; PRIORITY JOURNAL; REVIEW; SCREENING; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

HUMANS; IMMUNOTHERAPY; MYOCARDITIS;

EID: 85064726685     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000622     Document Type: Review

References (24)

1. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016; 375: 1845-1855.
2. Eggermont AM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018; 378: 1789-1801.
3. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378: 158-168.
4. Heery CR, Coyne GH, Madan RA, et al. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. J Clin Oncol 2014; 32(15_suppl):3064.
5. Escudier M, Cautela J, Malissen N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 2017; 136:2085-2087.
6. Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018; 19:1579-1589.
7. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016; 375:1749-1755.
8. Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 2016; 4:50.
9. Tang J, Yu JX, Hubbard-Lucey VM, et al. Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov 2018; 17:854-855.
10. Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet (Lond, Engl) 2018; 391:933.
11. Al-Kindi SG, Oliveira GH. Reporting of immune checkpoint inhibitor-associated myocarditis. Lancet (Lond, Engl) 2018; 392:382-383.
12. Hu YB, Zhang Q, Li HJ, et al. Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in nonsmall cell lung cancer: a meta-analysis. Transl Lung Cancer Res 2017; 6(Suppl 1): S8-s20.
13. Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018; 71:1755-1764.
14. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34:2636-2648. (2648a-2648d).
15. Raschi E, Diemberger I, Poluzzi E, De Ponti F. Reporting of immune checkpoint inhibitor-associated myocarditis. Lancet (Lond, Engl) 2018; 392:383.
16. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transpl 2005; 24:1710-1720.
17. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36:1714-1768.
18. Arangalage D, Delyon J, Lermuzeaux M, et al. Survival after fulminant myocarditis induced by immune-checkpoint inhibitors. Ann Intern Med 2017; 167:683-684.
19. Gallegos C, Rottmann D, Nguyen VQ, Baldassarre LA. Myocarditis with checkpoint inhibitor immunotherapy: case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate. Eur Heart J-Case Reports 2019; yty149; https://doi.org/10.1093/ehjcr/ yty149.
20. Jain V, Mohebtash M, Rodrigo ME, et al. Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin. J Immunother (Hagerstown, MD: 1997) 2018; 41:332-335.
21. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebocontrolled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 2003; 107:3133-3140.
22. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136:e137-e161.
23. Murray LK, Gonzalez-Costello J, Jonas SN, et al. Ventricular assist device support as a bridge to heart transplantation in patients with giant cell myocarditis. Eur J Heart Fail 2012; 14:312-318.
24. Lyon AR, Yousaf N, Battisti NM, et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 2018; 19:e447-e458.